Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Receivables - Other: 2019-2025

Historic Receivables - Other for Corcept Therapeutics (CORT) over the last 6 years, with Sep 2025 value amounting to $3.9 million.

  • Corcept Therapeutics' Receivables - Other rose 34.48% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 34.48%. This contributed to the annual value of $4.1 million for FY2024, which is 70.71% down from last year.
  • Corcept Therapeutics' Receivables - Other amounted to $3.9 million in Q3 2025, which was down 4.88% from $4.1 million recorded in Q2 2025.
  • Over the past 5 years, Corcept Therapeutics' Receivables - Other peaked at $18.2 million during Q1 2025, and registered a low of $900,000 during Q3 2022.
  • Over the past 3 years, Corcept Therapeutics' median Receivables - Other value was $4.1 million (recorded in 2025), while the average stood at $8.5 million.
  • Per our database at Business Quant, Corcept Therapeutics' Receivables - Other surged by 1,455.56% in 2023 and then plummeted by 85.71% in 2024.
  • Corcept Therapeutics' Receivables - Other (Quarterly) stood at $1.4 million in 2021, then skyrocketed by 900.00% to $14.0 million in 2022, then remained steady at $14.0 million in 2023, then tumbled by 70.71% to $4.1 million in 2024, then soared by 34.48% to $3.9 million in 2025.
  • Its Receivables - Other was $3.9 million in Q3 2025, compared to $4.1 million in Q2 2025 and $18.2 million in Q1 2025.